Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2020 Results
Rafael Holdings, Inc. (NYSE: RFL) reported revenue of $4.9 million and a loss per share of $0.66 for the fiscal year ending July 31, 2020. Fourth quarter revenue matched last year's at $1.2 million, but the loss per share widened from $0.16 to $0.34 due to increased investments in the Barer Institute. The company also achieved full enrollment for its pivotal Phase 3 clinical trial for metastatic pancreatic cancer. The FDA granted Orphan Drug Designation for its lead compound, CPI-613®, for treating soft tissue sarcoma.
- Secured FDA Orphan Drug Designation for CPI-613®.
- Full enrollment achieved in Phase 3 trial for metastatic pancreatic cancer.
- Majority stake increased in LipoMedix to 67%.
- Loss per share increased from $0.16 to $0.34 year-over-year.
- Total cash and cash equivalents decreased from $12.0 million to $6.2 million.
- Consolidated net loss widened to $10.4 million from $4.7 million year-over-year.
NEWARK, N.J., Oct. 29, 2020 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of
Q4 FY 2020 Consolidated Highlights
- Revenue of
$1.2 million in Q4 FY2020, generated by Rafael Holdings' real estate portfolio, was unchanged from the year-ago quarter. The loss per share of$0.34 increased from$0.16 in the year ago quarter largely due to additional investment in the Company's wholly owned pharmaceutical research venture, the Barer Institute. - In August after the quarter close, the company sold its commercial real estate property in Piscataway, New Jersey for
$3.9 million
Rafael Pharmaceuticals
At July 31, 2020, the Company and its subsidiaries collectively owned securities representing
- The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for Rafael Pharma's lead compound, CPI-613® (devimistat), for the treatment of soft tissue sarcoma. Rafael's clinical trial will focus on the treatment of relapsed or refractory clear cell sarcoma.
- Ono Pharmaceutical Co., has begun a multicenter, open-label Phase 1 study in Japan for patients with pancreatic cancer. The study is evaluating the efficacy and safety of CPI-613®️ (devimistat) in combination with modified FOLFIRINOX (mFFX).
- Rafael Pharma reached its target enrollment of 500 patients in its pivotal Phase 3 clinical trial for metastatic pancreatic cancer (AVENGER 500). The trial is evaluating the efficacy and safety of CPI-613®️ (devimistat) in combination with modified FOLFIRINOX (mFFX) as first-line therapy. Efficacy data for this trial could be available for analysis as early as the second quarter of calendar year 2021.
- Rafael Pharma has crossed the midpoint to its first interim analysis in enrollment for its pivotal Phase 3 clinical trial (ARMADA 2000) of CPI-613® (devimistat) for relapsed or refractory acute myeloid leukemia (AML). The multicenter, open-label, randomized pivotal trial is evaluating the efficacy and safety of its lead compound devimistat in combination with high dose cytarabine and mitoxantrone (CHAM) in older patients. The efficacy data for this trial couuld be available for interim analysis as early as the second quarter of calendar year 2021.
- Rafael Pharma expanded its Phase 2 clinical trial of CPI-613® (devimistat) for patients with relapsed or refractory Burkitt's lymphoma/leukemia.
- Rafael Pharma entered into a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the effects of CPI-613® (devimistat) with or without chemotherapy agents, including oxaliplatin/cisplatin/5-FU/carboplatin/taxol, on esophageal cancer cells.
LipoMedix
At July 31, 2020, Rafael Holdings held
Barer Institute
The Barer Institute has identified and begun to evaluate new therapeutic compounds, including compounds to regulate cancer metabolism, through internal development and in-licensing. It is working to validate newly discovered biomarkers for resistance and sensitivity within its portfolio compounds and to identify certain novel targetable mechanisms of action. In addition, the Barer Institute has identified several potential lead compounds for clinical development and found combinations that may meaningfully increase the efficacy of certain clinical compounds.
Remarks by Howard Jonas, Chairman and CEO of Rafael Holdings
"Rafael Holdings' continued to execute on our strategic vision in the fourth quarter, selling our Piscataway property and further increasing our majority stake in LipoMedix. In August, Rafael Pharma announced a major milestone – fully enrolling its pivotal Phase 3 Avenger 500 study for patients with metastatic pancreatic cancer. Results could be available as early as the second quarter of 2021. The Barer Institute has multiple compounds under development and collaboration programs in process with some of the premier academic centers in the country."
About Rafael Holdings, Inc.:
Rafael Holdings is focused on development of novel cancer therapies. The company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. Through its wholly owned Barer Institute subsidiary, the company is developing compounds focused on the regulation of cancer metabolism. The company also holds commercial real estate assets in New Jersey and Jerusalem. For more information, visit our website at rafaelholdings.com.
Rafael Holdings, Inc. Consolidated Balance Sheet (in thousands except for share and per share data) | ||||||||
July 31, | ||||||||
2020 | 2019 | |||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash and cash equivalents | $ | 6,206 | $ | 12,024 | ||||
Trade accounts receivable, net of allowance for doubtful accounts of | 267 | 450 | ||||||
Due from Rafael Pharmaceuticals | 118 | 280 | ||||||
Prepaid expenses and other current assets | 273 | 507 | ||||||
Assets held for sale | 2,968 | — | ||||||
Total current assets | 9,832 | 13,261 | ||||||
Property and equipment, net | 44,433 | 48,733 | ||||||
Equity investment – RP Finance | 192 | — | ||||||
Investments – Rafael Pharmaceuticals | 70,018 | 70,018 | ||||||
Investments – Other Pharmaceuticals | 1,201 | 2,000 | ||||||
Investments – Hedge Funds | 7,510 | 5,125 | ||||||
Deferred income tax assets, net | 6 | 19 | ||||||
In-process research and development and patents | 1,575 | 1,575 | ||||||
Other assets | 1,580 | 1,412 | ||||||
TOTAL ASSETS | $ | 136,347 | $ | 142,143 | ||||
LIABILITIES AND EQUITY | ||||||||
CURRENT LIABILITIES | ||||||||
Trade accounts payable | $ | 921 | $ | 795 | ||||
Accrued expenses | 1,191 | 605 | ||||||
Amount due for purchase of membership interest | 3,500 | — | ||||||
Other current liabilities | 115 | 27 | ||||||
Total current liabilities | 5,727 | 1,427 | ||||||
Due to related parties | — | 65 | ||||||
Convertible debt, net of discount of | — | 14,946 | ||||||
Other liabilities | 92 | 292 | ||||||
Accrued interest on convertible debt - Related Party | — | 649 | ||||||
TOTAL LIABILITIES | 5,819 | 17,379 | ||||||
COMMITMENTS AND CONTINGENCIES | ||||||||
EQUITY | ||||||||
Class A common stock, | 8 | 8 | ||||||
Class B common stock, | 149 | 131 | ||||||
Additional paid-in capital | 129,136 | 112,898 | ||||||
Accumulated deficit | (16,255) | (5,840) | ||||||
Accumulated other comprehensive income related to foreign currency translation adjustment | 3,762 | 3,784 | ||||||
Total equity attributable to Rafael Holdings, Inc. | 116,800 | 110,981 | ||||||
Noncontrolling interests | 13,728 | 13,783 | ||||||
TOTAL EQUITY | 130,528 | 124,764 | ||||||
TOTAL LIABILITIES AND EQUITY | $ | 136,347 | $ | 142,143 | ||||
Rafael Holdings, Inc. Consolidated Statement of Operations (in thousands except for share and per share data) | ||||||||
Year Ended July 31, | ||||||||
2020 | 2019 | |||||||
REVENUES | ||||||||
Rental – Third Party | $ | 1,516 | $ | 1,452 | ||||
Rental – Related Party | 2,082 | 2,125 | ||||||
Parking | 832 | 874 | ||||||
Other – Related Party | 480 | 480 | ||||||
Total Revenue | 4,910 | 4,931 | ||||||
COSTS AND EXPENSES | ||||||||
Selling, general and administrative | 9,118 | 8,821 | ||||||
Research and development | 2,391 | 1,027 | ||||||
Depreciation | 1,866 | 1,779 | ||||||
Loss from operations | (8,465) | (6,696) | ||||||
Interest (expense) income, net | (32) | 469 | ||||||
Net (loss) gain resulting from foreign exchange transactions | (5) | 47 | ||||||
Gain on sale of marketable securities | — | 330 | ||||||
Impairment of investments - Other Pharmaceuticals | (799) | — | ||||||
Unrealized gain on investments - Hedge Funds | 2,385 | 907 | ||||||
Loss before income taxes | (6,916) | (4,943) | ||||||
(Provision for) benefit from income taxes | (29) | 19 | ||||||
Impairment of equity method investment of Altira | (4,000) | — | ||||||
Equity in earnings of RP Finance | 192 | — | ||||||
Consolidated net loss | (10,753) | (4,924) | ||||||
Net loss attributable to noncontrolling interests | (338) | (231) | ||||||
Net loss attributable to Rafael Holdings, Inc. | $ | (10,415) | $ | (4,693) | ||||
OTHER COMPREHENSIVE LOSS | ||||||||
Net Loss | $ | (10,753) | $ | (4,924) | ||||
Foreign Currency Translation Adjustment | (22) | 298 | ||||||
Total Comprehensive Loss | (10,775) | (4,626) | ||||||
Comprehensive (loss) income attributable to noncontrolling interests | (9) | 173 | ||||||
Total Comprehensive loss attributable to Rafael Holdings, Inc. | $ | (10,784) | $ | (4,453) | ||||
Loss per share | ||||||||
Basic and Diluted | $ | (0.66) | $ | (0.35) | ||||
Weighted average number of shares used in calculation of loss per share | ||||||||
Basic and Diluted | 15,764,829 | 13,275,239 | ||||||
Rafael Holdings, Inc. Consolidated Statement of Cash Flows (in thousands) | ||||||||
Year Ended July 31, | ||||||||
2020 | 2019 | |||||||
Operating activities | ||||||||
Net loss | $ | (10,753) | $ | (4,924) | ||||
Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
Depreciation | 1,866 | 1,779 | ||||||
Deferred income taxes | 13 | (19) | ||||||
Interest income on Rafael Pharmaceuticals Series D Convertible Note | — | (848) | ||||||
Interest income | — | (37) | ||||||
Net gain on sale of marketable securities | — | (330) | ||||||
Net unrealized gain on investments - Hedge Funds | (2,385) | (907) | ||||||
Impairment of investments - Other Pharmaceuticals | 799 | — | ||||||
Impairment of equity method investment of Altira | 4,000 | — | ||||||
Equity in earnings of RP Finance | (192) | — | ||||||
Provision for doubtful accounts | 96 | 122 | ||||||
Noncash compensation | 684 | 372 | ||||||
Amortization of debt discount | 54 | 17 | ||||||
Write-off of patents | — | 76 | ||||||
Change in assets and liabilities: | ||||||||
Trade accounts receivable | 87 | (285) | ||||||
Prepaid expenses and other current assets | 234 | (86) | ||||||
Other assets | (168) | 275 | ||||||
Accounts payable and accrued expenses | 713 | 533 | ||||||
Other current liabilities | 88 | 3 | ||||||
Due to related parties | (65) | 654 | ||||||
Due from related parties | 162 | (280) | ||||||
Accrued interest - Related Party | 19 | 649 | ||||||
Other liabilities | 82 | 104 | ||||||
Net cash used in operating activities | (4,666) | (3,132) | ||||||
Investing activities | ||||||||
Purchase of investment in Altira | (500) | — | ||||||
Purchases of property and equipment | (534) | (399) | ||||||
Proceeds from sale and maturity of marketable securities | — | 25,031 | ||||||
Investment in Rafael Pharmaceuticals | — | (55,870) | ||||||
Net cash used in investing activities | (1,034) | (31,238) | ||||||
Financing activities | ||||||||
Contribution from noncontrolling interest of consolidated entity | — | 4,587 | ||||||
Repayment of loan from Rafael Pharmaceuticals, including interest | — | 3,335 | ||||||
Proceeds from exercise of options | 29 | 190 | ||||||
Proceed from sale of shares | — | 7,777 | ||||||
Proceeds from issuance of convertible note | — | 15,000 | ||||||
Payments for taxes related to shares withheld for employee taxes | (125) | — | ||||||
Net cash (used in) provided by financing activities | (96) | 30,889 | ||||||
Effect of exchange rate changes on cash and cash equivalents | (22) | (298) | ||||||
Net decrease in cash and cash equivalents | (5,818) | (3,779) | ||||||
Cash and cash equivalents, beginning of year | 12,024 | 15,803 | ||||||
Cash and cash equivalents, end of year | $ | 6,206 | $ | 12,024 | ||||
Supplemental Schedule of Noncash Investing and Financing Activities | ||||||||
Adoption effect of ASU 2016-01 | $ | — | $ | 39 | ||||
Beneficial conversion feature of convertible debt - Related Party | $ | — | $ | 71 | ||||
Debt and accrued interest converted to Series D Preferred Stock | $ | — | $ | 10,848 | ||||
Related Party deposit utilized to purchase Class B Common Stock | $ | — | $ | 864 | ||||
Amount due for purchase of membership interest | $ | 3,500 | $ | — | ||||
Transfer of asset held for sale | $ | 2,968 | $ | — | ||||
Conversion of LipoMedix Bridge Notes | $ | 283 | $ | — | ||||
Conversions of related party convertible notes payable and accrued interest | $ | 15,668 | $ | — | ||||
View original content:http://www.prnewswire.com/news-releases/rafael-holdings-reports-fourth-quarter-and-full-fiscal-year-2020-results-301163394.html
SOURCE Rafael Holdings, Inc.
FAQ
What were Rafael Holdings' revenue and loss per share for FY 2020?
What key developments occurred in Rafael Holdings' clinical trials?
How did Rafael Holdings' financial performance change in Q4 FY 2020?
What stake does Rafael Holdings hold in Rafael Pharmaceuticals?
